Acute myeloid leukemia
Disease and Cancer
ChemGenex’s Marketing Authorization Application for Omacetaxine Mepesuccinate Validated by the European Medicines AgencyThe company is developing omacetaxine, its lead product candidate, for the treatment of patients with Chronic Myeloid Leukemia (CML), Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS). A New Drug Application has been... In this article: FDA, European Medicines Agency, Chronic Myeloid Leukemia, Oxygen, Cyclin-D1, Cancer, and Acute myeloid leukemia |
-
ScienceDaily: Latest Science News | 1 day ago
New tools for prediction of disease progression in acute childhood leukemia
...For Treating Some Forms Of Leukemia (Jan. 29, 2008) The drug sorafenib, which is used to treat kidney and liver cancer, may be effective acute myeloid leukemia patients with specific gene mutations. Previous studies have shown that sorafenib...
In this article: Leukemia, Cancer, Uppsala University, and Acute lymphoblastic leukemia
-
Medical News Today | 3 days ago
New Role Of IDH1 Gene Mutation In Brain Cancer Revealed By Cancer Metabolism Discovery
...known to have the IDH1 mutation. Recently, the IDH1 mutation was also shown to be present in a significant percentage of patients with Acute Myeloid Leukemia, another devastating disease. The insight from this new research at Agios is the...
In this article: Cancer, Glioma, 2-hydroxyglutarate, Nature, Medical advice, Beth Israel Deaconess Medical Center, and Amino acid
-
PR Newswire: Health / Biotech | November 19, 2009
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
See more news releases in: Biotechnology Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the...
In this article: Human Genome Sciences, Cytarabine, Oligonucleotide, Hepatocellular carcinoma, The Leukemia and Lymphoma Society, North America, and Hong Kong
-
CNN | November 18, 2009
Beautiful bright lights shine for dying boy
...he will make it to Christmas, so we wanted to have Christmas early," Julie Locke told local news station WMBD. ACUTE MYELOID LEUKEMIA Acute myeloid leukemia is a cancer that forms in cells that normally would become blood cells. Neighbor...
In this article: Halloween, Cancer, E mail, Detroit Tigers, and United States
-
Finding May Give Hope To More Leukemia Patients So They May Live Cancer-Free
...2008. The average age of the patients in this study was 16 years. Eighty-eight patients had acute lymphoblastic leukemia (ALL) and 89 had acute myeloid leukemia (AML). "Our analysis showed that patients in first or second remission from...
In this article: Leukemia, Cancer, University of Minnesota, Medical advice, Chronic myelogenous leukemia, Antibiotic, and Acute lymphoblastic leukemia
-
Reality TV Magazine | November 15, 2009
Extreme Makeover Home Edition: Stott Family and David Duchovney!
...to the state of Lena, Illinois where ABC's Extreme Makeover Home Edition will build the Stott family a new home. Joey was diagnosed with acute myeloid leukemia, and got a bone marrow transplant in 2004, which sent the disease into remission.
In this article: Ty and Extreme Makeover Home Edition
-
St. Petersburg Times | November 15, 2009
The Great American Smokeout can help you quit for good
In this article: Lung cancer, Tobacco, American Cancer Society, Chantix, Cancer, Suicide, Acupuncture, and Chronic bronchitis
-
Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia
(Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in...
In this article: FDA, Cancer, Cytarabine, United States, Medical advice, Derivative, Platinum, and Pharmaceutical
-
Sunesis Completes Enrollment Of Voreloxin REVEAL-1 Trial In Acute Myeloid Leukemia
...Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy.
In this article: Cancer, Cytarabine, Medical advice, Accrual, Derivative, Trademark, and Platinum
-
Prime Newswire | October 28, 2009
Cyclacel Pharmaceuticals Reports Survival Data From Phase 2 Sapacitabine Study in Elderly Patients With Acute Myeloid Leukemia
...primary endpoint of the Phase 2 study of sapacitabine as a treatment for elderly patients aged 70 or older with either newly diagnosed acute myeloid leukemia (AML) or AML in first relapse. The study was a three-arm randomized trial...
In this article: Cyclacel, Trademark, Tipifarnib, Seliciclib, Cancer, All rights reserved, Dermatitis, and Nucleoside
Trends
Loading...
More on Acute myeloid leukemia
Description from Wikipedia:
Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of white blood cells, characterized by the rapid proliferation of abnormal cells which accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.
The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, resulting in a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Although several risk factors for AML have been identified, the specific cause of AML remains unclear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.
Acute myeloid leukemia is a potentially curable disease; but only a minority of patients are cured with current therapy. AML is treated initially with chemotherapy aimed at inducing a remission; some patients may go on to receive a hematopoietic stem cell transplant.
Areas of active research in acute myeloid leukemia include further elucidation of the cause of AML, identification of better prognostic indicators, development of new methods of detecting residual disease after treatment, and the development of new drugs and targeted therapies.
Explore everything named Acute myeloid leukemia...
